Drug Profile

Bepranemab - UCB Biopharma

Alternative Names: RG-6416; UCB-0107

Latest Information Update: 12 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UCB Biopharma
Class Antibodies; Antidementias; Monoclonal antibodies; Neuroprotectants
Mechanism of Action Tau protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alzheimer's disease
No development reported Progressive supranuclear palsy

Most Recent Events

31 Oct 2024 Efficacy and adverse events data from the phase IIa TOGETHER (AH0003) trial in Alzheimer’s disease released by UCB
22 Oct 2024 Bepranemab is no longer licensed to Genentech
09 May 2024 Roche plans to submit regulatory application for Alzheimer's disease in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com